Bioxcel therapeutics reports financial results for the fourth quarter and full year 2024

Enrollment exceeds 60% of required number of patients in serenity at-home pivotal phase 3 safety trial evaluating 200 patients for acute treatment of agitation associated with bipolar disorders or schizophrenia topline data expected in second half of 2025 intended to support potential snda submission for label expansion of igalmi ® in the at-home setting strengthened cash position to advance bxcl501 program new haven, conn., march 27, 2025 (globe newswire) -- bioxcel therapeutics, inc. (nasdaq: btai), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today reported its financial results for the fourth quarter and full year 2024.
BTAI Ratings Summary
BTAI Quant Ranking